Abbott Cuts Top End of 2025 Guidance as Tariff Threat Looms (3)

Abbott Laboratories cut the top end of its 2025 earnings guidance by 2 cents a share, just as the Trump administration launched an investigation into the medical device sector that could lead to tariffs on its biggest product category.

The company now expects earnings to fall between $5.12 and $5.18 a share this year. In July, the company narrowed its adjusted earnings guidance for the year to a range of $5.10 to $5.20 a share.

Adjusted earnings in the third quarter were $1.30 a share, the Abbott Park, Illinois-based company said in a statement, in line with the average ...